IL6 and temporal arteritis: Since then, we have treated other 14 GCA patients (who had failed on corticosteroids and/or TCZ, or where IL-6-blocking regimen with TCZ was considered inappropriate due to increased risk of, or impaired ability to diagnose, infections) with baricitinib or tofacitinib for ≥6 months, and the retrospective data of these patients are summarized herein.